Lazard Asset Management
AUTL icon

Lazard Asset Management’s Autolus Therapeutics AUTL Stock Holding History

Lazard Asset Management’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-178
Closed – – 2306
2024
Q4 		$0 Hold
178
– – ﹤0.01% 2280
2024
Q3 		$0 Sell
178
-305
-63% -$1.22K ﹤0.01% 2264
2024
Q2 		$1K Sell
483
-6,889
-93% -$29.7K ﹤0.01% 2125
2024
Q1 		$46K Sell
7,372
-4,179
-36% -$26.1K ﹤0.01% 1731
2023
Q4 		$74K Buy
11,551
+531
+5% +$2.02K ﹤0.01% 1771
2023
Q3 		$25K Buy
11,020
+469
+4% +$1.34K ﹤0.01% 2063
2023
Q2 		$24K Buy
10,551
+383
+4% +$909 ﹤0.01% 2065
2023
Q1 		$18K Buy
10,168
+6,416
+171% +$12.5K ﹤0.01% 2065
2022
Q4 		$7K Buy
+3,752
New +$9.49K ﹤0.01% 2227

Other funds holding AUTL

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $39B AUM 18.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Lazard Asset Management's AUTL Position: Q1 2025 in Review

Lazard Asset Management sold out of Autolus Therapeutics (AUTL) in Q1 2025, closing a stake of 178 shares.

Lazard Asset Management first reported a position in AUTL in Q4 2022 and held it in 9 quarters. The position peaked at $74K in Q4 2023. 95 funds tracked by Wall St. Rank hold AUTL as of Q1 2025.

  • Lazard Asset Management reported no remaining Autolus Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Lazard Asset Management sold 178 Autolus Therapeutics shares in Q1 2025.
  • Lazard Asset Management first reported a position in Autolus Therapeutics in Q4 2022 and held it in 9 quarters.
  • Lazard Asset Management's Autolus Therapeutics position peaked at $74K in Q4 2023.
  • 95 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2025.

Based on Lazard Asset Management's 13F filing for Q1 2025, filed 15 May 2025.